

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Dimethyl fumarate for treating moderate to severe plaque psoriasis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| Not applicable. |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No issues were raised. |

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| Based on the committee's previous experience of technology appraisals in psoriasis, it was aware that the Psoriasis Area and Severity Index (PASI) can underestimate disease severity in those with black or brown skin, and that the Dermatology Life Quality Index (DLQI) has limited validity in some people, and may also miss anxiety and depression. Therefore, it included a recommendation that when using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and |

make any adjustments they consider appropriate. It also included a recommendation than when using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.23 of the final appraisal determination document.

Approved by Associate Director (name): Elisabeth George

Date: 10/07/2017